TG Therapeutics price target raised to $28 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on TG Therapeutics to $28 from $24 and keeps a Buy rating on the shares. The analyst lowered the firm’s Q2 sales estimate for Briumvi to $10.4M from $10.6M, but increased its Briumvi sales estimates for the latter half of the year, which brings its 2023 Briumvi sales estimate to $47.1M from $46.1M. A potential European approval is expected to be about six to nine months behind the U.S. approval, the analyst tells investors in a research note.